Menlo Therapeutics (NASDAQ:MNLO) issued its quarterly earnings results on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.15, Bloomberg Earnings reports.
Shares of NASDAQ MNLO traded down $0.01 during midday trading on Friday, reaching $3.46. The company had a trading volume of 45,208 shares, compared to its average volume of 42,134. Menlo Therapeutics has a one year low of $3.37 and a one year high of $12.00. The company’s fifty day simple moving average is $5.20. The company has a market cap of $90.72 million, a PE ratio of -1.46 and a beta of 2.40.
Several equities research analysts have issued reports on MNLO shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $25.00 price target on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Zacks Investment Research lowered Menlo Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. Finally, ValuEngine raised Menlo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday.
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.
Featured Story: What is a price target?
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.